Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Nova Drug Patent Portfolio

Nova owns 1 orange book drug protected by 1 US patent Given below is the list of Nova's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12409156 Stable Aqueous Hydroxycarbamide Solution 23 Dec, 2041
Active


Given below is the list of recent legal activities going on the following drug patents of Nova.

Activity Date Patent Number
Patent litigations
Recordation of Patent Grant Mailed 16 Sep, 2025 US12409156
Email Notification 09 Sep, 2025 US12409156
Patent eGrant Notification 09 Sep, 2025 US12409156
Recordation of Patent eGrant 09 Sep, 2025 US12409156
Mail Patent eGrant Notification 09 Sep, 2025 US12409156
Patent Issue Date Used in PTA Calculation 09 Sep, 2025 US12409156
Email Notification 28 Aug, 2025 US12409156
Issue Notification Mailed 27 Aug, 2025 US12409156
Dispatch to FDC 20 Aug, 2025 US12409156
Application Is Considered Ready for Issue 20 Aug, 2025 US12409156
Issue Fee Payment Received 15 Aug, 2025 US12409156
Issue Fee Payment Verified 15 Aug, 2025 US12409156
Mail Notice of Allowance 12 Aug, 2025 US12409156
Notice of Allowance Data Verification Completed 11 Aug, 2025 US12409156
Date Forwarded to Examiner 29 Jul, 2025 US12409156


Nova's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Nova:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia Novartis Pharmaceuticals NA ACTIVE NOT RECRUITING
(Oct, 2024)
PHASE2
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC Novartis Pharmaceuticals NA ACTIVE NOT RECRUITING
(Sep, 2024)
PHASE4
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients Novartis Pharmaceuticals NA COMPLETED
(Jul, 2023)
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients Novartis Pharmaceuticals NA COMPLETED
(Mar, 2023)
PHASE4
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction Novartis Pharmaceuticals NA COMPLETED
(Mar, 2020)
PHASE4
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction Novartis Pharmaceuticals NA COMPLETED
(Feb, 2019)
PHASE3
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension Novartis Pharmaceuticals NA COMPLETED
(Oct, 2015)
PHASE2
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection Novartis Pharmaceuticals NA COMPLETED
(Jul, 2012)
PHASE3


Nova Drug List

Given below is the complete list of Nova's drugs and the patents protecting them.


1. Xromi

Xromi is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12409156 Stable Aqueous Hydroxycarbamide Solution 23 Dec, 2041
(15 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xromi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List